# Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients

Study · id `cardio:ct-nct07073768` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07073768](<https://clinicaltrials.gov/study/NCT07073768>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07073768

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 126 participants.

## Technical summary

Registry record NCT07073768. Randomized; no masking; primary purpose treatment. Start 2025-07-01 (actual); primary completion 2026-12-26 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 126 participants (planned count; ClinicalTrials.gov record NCT07073768, source copy `cardio:ctgov-nct07073768-2025-07-18`, retrieved 2026-10-26)
- Started: 2025-07-01 (actual) (ClinicalTrials.gov record NCT07073768, source copy `cardio:ctgov-nct07073768-2025-07-18`, retrieved 2026-10-26)
- Primary completion: 2026-12-26 (anticipated) (ClinicalTrials.gov record NCT07073768, source copy `cardio:ctgov-nct07073768-2025-07-18`, retrieved 2026-10-26)
- Completion: 2026-12-30 (anticipated) (ClinicalTrials.gov record NCT07073768, source copy `cardio:ctgov-nct07073768-2025-07-18`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT07073768, source copy `cardio:ctgov-nct07073768-2025-07-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07073768-2025-07-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients
- Condition: Diabetes Mellitus Type 2
- Condition: Glycemic Control for Diabetes Mellitus
- Intervention (Drug): Trelagliptin 100 mg
- Intervention (Drug): Sitagliptin 100mg OD
- Lead sponsor: Khyber Medical College, Peshawar
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: d20e4ad1e8e3c08c8a3ad72db43f8b5d54ba52af85d3984fe18c408b4f4882ab
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
